Content area

|
|

Antikoagulerende behandling ved kardiovertering af atrieflimren

Forfatter(e)
Anita Andersen1, Axel Brandes2, Morten Würtz3, Morten Lock Hansen4 & Erik Lerkevang Grove1, 5
1) Hjertesygdomme, Aarhus Universitetshospital 2) Hjertemedicinsk Afdeling B, Odense Universitetshospital 3) Afdeling for Hjertesygdomme, Hospitalsenheden Vest, Herning 4) Afdeling for Hjertesygdomme, Gentofte Hospital 5) Institut for Klinisk Medicin, Health, Aarhus Universitet

Ugeskr Læger 2019;181:V09180640

Reference: 
Ugeskr Læger 2019;181:V09180640

Anita Andersen, Axel Brandes, Morten Würtz,
Morten Lock Hansen & Erik Lerkevang Grove:

Anticoagulant therapy of patients undergoing cardioversion for atrial fibrillation

Ugeskr Læger 2019;181:V09180640

Cardioversion of atrial fibrillation entails a risk of thromboembolic events, especially ischaemic stroke. Oral anticoagulation therapy before and after cardioversion is therefore crucial. Assessing ischaemic stroke risk and time of arrhythmia onset is important when deciding on the optimal anticoagulation strategy. For decades, vitamin K antagonists (VKA) have been the primary anticoagulant drugs used in relation to cardioversion, but non-VKA oral anticoagulants may be preferred because of their rapid onset of action and predictable anticoagulant effect without the need for monitoring.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Søren Dalsgaard | 20/05
1 Kommentar
af Anette Bygum | 19/05
10 kommentarer
af Hans-Iver G. F.-D Kley | 18/05
1 Kommentar
af Per Bonding | 17/05
1 Kommentar
af Jakob Ramlau | 15/05
1 Kommentar